{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:19:57Z","timestamp":1788265197538,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis B virus (HBV) infection remains a major global health challenge. Peginterferon-\u03b1 (PEG-IFN-\u03b1) and nucleos(t)ide analogs (NAs) are standard therapies used to suppress HBV replication. Although HBsAg clearance and seroconversion are ideal therapeutic endpoints, whether PEG-IFN-\u03b1 combined with NAs offers superior efficacy compared with PEG-IFN-\u03b1 monotherapy remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Controlled clinical trials published between 2000 and 2025 that compared PEG-IFN-\u03b1 plus NA combination therapy with PEG-IFN-\u03b1 monotherapy in patients with chronic hepatitis B, with treatment duration \u2265 48 weeks, were included. The primary outcomes were HBsAg clearance and seroconversion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven trials involving 2,439 patients were identified and analyzed. After 48 weeks of treatment, the HBsAg clearance rate was significantly higher in the combination therapy group than in the monotherapy group [odds ratio (OR) = 1.59, 95% confidence interval (CI): 1.01\u20132.52,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.05]. However, no significant difference in HBsAg clearance rates was observed between the two groups at 24 weeks of post-treatment follow-up (OR = 1.33, 95% CI: 0.76\u20132.33,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.31). Likewise, no significant differences were found in HBsAg seroconversion rates after 48 weeks of treatment or at 24 weeks post-treatment follow-up (OR = 1.77, 95% CI: 0.94\u20133.32,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.08; and OR = 1.42, 95% CI: 0.88\u20132.28,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.15, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PEG-IFN-\u03b1 promotes HBsAg clearance and seroconversion. Combination therapy with PEG-IFN-\u03b1 plus NAs yields higher short-term clearance than monotherapy; however, sustained benefits appear to require prolonged treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1716225","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:13:33Z","timestamp":1767849213000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A meta-analysis of controlled clinical trials comparing peginterferon-\u03b1 plus nucleos(t)ide analogs versus peginterferon-\u03b1 monotherapy for HBsAg clearance or seroconversion in patients with chronic hepatitis B"],"prefix":"10.3389","volume":"12","author":[{"given":"Shuyao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.5009\/gnl240023","article-title":"Toward a functional cure for hepatitis B.","volume":"18","author":"Lok","year":"2024","journal-title":"Gut Liver"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/01.NPR.0000000000000246","article-title":"Overview of chronic hepatitis B management.","volume":"50","author":"Jun","year":"2025","journal-title":"Nurse Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/v17030388","article-title":"HBV reactivation in immunosuppressed patients: screening, prevention, and management including solid organ transplant recipients.","volume":"17","author":"Vutien","year":"2025","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/v17010042","article-title":"Incidence of HBV reactivation in psoriasis patients undergoing cytokine inhibitor therapy: a single-center study and systematic review with a meta-analysis.","volume":"17","author":"Kuo","year":"2024","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1136\/gutjnl-2024-332182","article-title":"High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy.","volume":"73","author":"Fan","year":"2024","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/MEG.0000000000002946","article-title":"Predictive value of serum HBV RNA on HBeAg seroconversion in treated chronic hepatitis B patients.","volume":"37","author":"Liu","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2259003","DOI":"10.1080\/22221751.2023.2259003","article-title":"The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment.","volume":"12","author":"Yin","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"B8","doi-asserted-by":"publisher","first-page":"99833","DOI":"10.3748\/wjg.v31.i3.99833","article-title":"C-X-C chemokine receptor type 5+CD8+ T cells as immune regulators in hepatitis Be antigen-positive chronic hepatitis B under interferon-alpha treatment.","volume":"31","author":"Xu","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1111\/liv.14897","article-title":"Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers.","volume":"41","author":"Wu","year":"2021","journal-title":"Liver Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: implications for diagnostics, therapy, and outcome.","volume":"81","author":"Zoulim","year":"2024","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jvh.14032","article-title":"Updated Guidelines for the Prevention and Management of Chronic Hepatitis B-World Health Organization 2024 Compared With China 2022 HBV Guidelines.","volume":"31","author":"Wong","year":"2024","journal-title":"J Viral Hepat"},{"key":"B12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.","volume":"83","year":"2025","journal-title":"J Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12876-017-0657-y","article-title":"Addition of nucleoside analogues to peg-IFN\u03b1-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFN\u03b1-2a: a randomized controlled trial.","volume":"17","author":"Xu","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1002\/jmv.28003","article-title":"Pegylated interferon-\u03b1-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for na\u00efve HBeAg-positive chronic hepatitis B patients: a prospective, multicenter, randomized controlled study.","volume":"94","author":"Lian","year":"2022","journal-title":"J Med Virol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.3390\/cancers15072142","article-title":"Prognostic role of the intrahepatic lymphatic system in liver cancer.","volume":"15","author":"Sakamoto","year":"2023","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e003224","DOI":"10.1136\/svn-2024-003224","article-title":"Percutaneous transluminal angioplasty and stenting (PTAS) in patients with symptomatic intracranial vertebrobasilar artery stenosis (IVBS).","volume":"10","author":"Pourahmad","year":"2025","journal-title":"Stroke Vasc Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1227\/NEU.0000000000001788","article-title":"Systematic analysis of publication bias in neurosurgery meta-analyses.","volume":"90","author":"Phua","year":"2022","journal-title":"Neurosurgery."},{"key":"B18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies.","volume":"22","author":"Barker","year":"2024","journal-title":"JBI Evid Synth"},{"key":"B19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/jvh.12018","article-title":"Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.","volume":"20","author":"Boglione","year":"2013","journal-title":"J Viral Hepat"},{"key":"B21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B.","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/hep.21302","article-title":"Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.","volume":"44","author":"ter Borg","year":"2006","journal-title":"Hepatology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3851\/IMP1466","article-title":"A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.","volume":"14","author":"Piccolo","year":"2009","journal-title":"Antivir Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1440-1746.2004.03209.x","article-title":"Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study.","volume":"19","author":"Dikici","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B.","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"105782","DOI":"10.1016\/j.antiviral.2023.105782","article-title":"Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.","volume":"221","author":"Zhao","year":"2024","journal-title":"Antiviral Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e70021","DOI":"10.1002\/jmv.70021","article-title":"HBV antigen-guided switching strategy From Nucleos(t)ide analogue to interferon: avoid virologic breakthrough and improve functional cure.","volume":"96","author":"Huang","year":"2024","journal-title":"J Med Virol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.14309\/ajg.0000000000002759","article-title":"Limited sustained remission after nucleos(t)ide analog withdrawal: results from a large, global, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B Study).","volume":"119","author":"Hirode","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/jcm12010361","article-title":"Short-Term Peg-IFN \u03b1-2b Re-treatment induced a high functional cure rate in patients with HBsAg Recurrence after Stopping Peg-IFN \u03b1-Based Regimens.","volume":"12","author":"Wu","year":"2023","journal-title":"J Clin Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1716225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:13:35Z","timestamp":1767849215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1716225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":33,"alternative-id":["10.3389\/fmed.2025.1716225"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1716225","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1716225"}}